Mosaic ImmunoEngineering Inc (CPMV) USD0.00001
No change
- Add to watchlist
- This stock can be held in a
No change
Business summary
Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing cancer therapies for areas of high unmet medical need. The Company has advanced an early-stage product candidate, MIE-101, that is based on a naturally occurring plant virus licensed from Case Western Reserve University (CWRU). Its product candidate, MIE-101, is based on a naturally occurring plant virus known as Cowpea mosaic virus (CPMV). The product is injected directly into a tumor and can act as an in-situ vaccine using markers of the injected tumor as the target which results in the activation of an immune response against the primary tumor and to prime systemic anti-tumor immunity, while reversing immunosuppressive signals in the tumor microenvironment (TME). In addition, the Company is pursuing new product candidates and platforms to expand its pipeline based on an understanding of immunotherapies and its license agreements with University of California San Diego.
Contact details
Important dates
General stock information
- Short code:
- CPMV
- ISIN:
- US61945M1018
- Market cap:
- $5.07 million
- Shares in issue:
- 7.24 million
- Sector:
- Semiconductors
- Exchange:
- Off Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.